Boriani Giuseppe, Imberti Jacopo F, Asteggiano Riccardo, Ameri Pietro, Mei Davide A, Farkowski Michał, Chun Julian, Merino Josè Luis, Lopez-Fernandez Teresa, Lyon Alexander R
Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo, 71, Modena 41124, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
Eur Heart J Digit Health. 2025 Jan 21;6(2):162-169. doi: 10.1093/ehjdh/ztae082. eCollection 2025 Mar.
The Council of Cardio-Oncology of the European Society of Cardiology developed an on-line anonymous survey to provide an overall picture of the current practice on the use of mobile and wearable digital devices in cardio-oncology and the potential barriers to their large-scale applicability.
Between June 2023 and January 2024, an online anonymous questionnaire was completed by 220 healthcare professionals from 55 countries. The greatest number of respondents reported that mobile/wearable digital devices have a role in all active cancer patients for measuring heart rate (33.9%), blood pressure (34.4%), body temperature (32.0%), physical activity (42.4%), and sleep (31.2%). In the setting of atrial fibrillation detection, respondents were evenly split between applying these technologies in all patients (33.0%) or only in selected patients (33.0%). Regarding QTc interval monitoring, 30.6% reported that mobile/wearable digital devices play a role only in selected patients. The decision to use the device was taken by the patient in 56.6% of cases and the physician in 43.4%. The most important barrier reported to mobile/wearable device implementation in the setting of cardiac rhythm monitoring and QTc measurement was their cost (weighted average: 3.38 and 3.39, respectively).
Mobile/wearable digital devices are considered to play an important role in different settings of cardio-oncology, including monitoring of patients' parameters and arrhythmia detection. Their role in monitoring physical activity and QTc interval appears more nuanced. The most important perceived barrier to mobile/wearable digital device implementation is considered their high cost.
欧洲心脏病学会心脏肿瘤学委员会开展了一项在线匿名调查，以全面了解心脏肿瘤学中移动和可穿戴数字设备的当前使用情况以及其大规模应用的潜在障碍。
2023年6月至2024年1月期间，来自55个国家的220名医疗保健专业人员完成了一份在线匿名问卷。报告称移动/可穿戴数字设备在所有活跃癌症患者中发挥作用的受访者数量最多，用于测量心率（33.9%）、血压（34.4%）、体温（32.0%）、身体活动（42.4%）和睡眠（31.2%）。在房颤检测方面，受访者在所有患者中应用这些技术（33.0%）或仅在选定患者中应用（33.0%）之间意见平分。关于QTc间期监测，30.6%的受访者报告称移动/可穿戴数字设备仅在选定患者中发挥作用。在56.6%的病例中，使用设备的决定由患者做出，在43.4%的病例中由医生做出。在心律监测和QTc测量中，报告的移动/可穿戴设备实施的最重要障碍是其成本（加权平均值分别为3.38和3.39）。
移动/可穿戴数字设备被认为在心脏肿瘤学的不同场景中发挥重要作用，包括监测患者参数和心律失常检测。它们在监测身体活动和QTc间期方面的作用似乎更为细微。移动/可穿戴数字设备实施的最重要感知障碍被认为是其高成本。
